Due to the ease of nanobody engineering, they can be employed in three nanobody-based therapeutic platforms: platform A, receptor antagonists to interfere with or block the activation of a certain ...

Laboratory of Bioorganic Chemistry, National Institutes of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States ...